13G Filing: James E. Flynn and Marinus Pharmaceuticals Inc (MRNS)

Page 2 of 13

Page 2 of 13 – SEC Filing

CUSIP No. 56854Q101 13G Page 2
of 10
1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Mgmt, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b) ☒

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

0

6.

SHARED VOTING POWER

2,238,587 (1)

7.

SOLE DISPOSITIVE POWER

0

8.

SHARED DISPOSITIVE POWER

2,238,587 (1)

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,238,587 (1)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES*

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

9.98%

12.

TYPE OF REPORTING PERSON*

PN

__________________

(1) Comprised of common stock held by Deerfield Special Situations
Fund, L.P., of which Deerfield Mgmt, L.P. is the general partner.

Follow Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)





Page 2 of 13